India Active Pharmaceutical Ingredients Industry: Size, Share, Demand & Market Outlook 2033 | Get Free Sample Report

According to IMARC Group’s report titled "India Active Pharmaceutical Ingredients Market Size, Share, Trends and Forecast by Drug Type, Manufacturer Type, Synthesis Type, Therapeutic Application, and Region, 2025-2033" the report offers a comprehensive analysis of the industry, including market share, growth, trends, and regional insights.

Note : We are in the process of updating our reports to cover the 20262034 forecast period. For the most recent data, insights, and industry updates, please click on "Request Free Sample Report".

Request Free Sample Report: https://www.imarcgroup.com/india-active-pharmaceutical-ingredients-market/requestsample

India Active Pharmaceutical Ingredients Market Overview

The size of active pharmaceutical ingredientsindustry inIndiareached USD 17.77 Billion in 2024. The market is projected to reach USD 38.60 Billion by 2033, exhibiting a compound annual growth rate (CAGR) of 8.10% during the forecast period from 2025 to 2033. This growth is driven by rising demand for generic drugs, government incentives promoting API self-reliance, patent expirations, increasing cases of chronic diseases, the expansion of biologics, cost advantages, increased foreign investments, export growth, research and development advancements, regulatory support, contract manufacturing, and biosimilars adoption.

India Active Pharmaceutical Ingredients Market Key Takeaways

• Current Market Size: USD 17.77 Billion (2024)


• CAGR: 8.10%


• Forecast Period: 2025-2033


• The Indian government has launched initiatives such as the Production Linked Incentive (PLI) scheme allocating INR 6,940 crore to boost domestic API manufacturing.


• Increased prevalence of chronic diseases like cardiovascular diseases, diabetes, and cancer is driving demand for APIs.


• By 2030, non-communicable diseases (NCDs) are expected to contribute about 67% of India's disease burden.


• Government’s Pharmaceuticals Vision 2020 with Rs.15,000 crore budget encourages India as a leading global pharmaceutical manufacturing hub.


• Expansion in contract manufacturing and biosimilars adoption is fueling API market growth.

India Active Pharmaceutical Ingredients Market Growth Factors

• Rising demand for generic pharmaceuticals in both domestic and international markets is a key growth driver.


• Government initiatives like the Production Linked Incentive (PLI) scheme with an allocation of INR 6,940 crore foster domestic API manufacturing.


• Patent expirations have increased the production and supply of generic APIs.


• Increasing burden of chronic diseases such as cardiovascular diseases, diabetes, and cancer requires consistent API supply for drug manufacturing.


• Growing biologics market expansion and biosimilars adoption support API demand.


• Cost advantages and a robust chemical manufacturing infrastructure enhance India's competitive positioning as a global API manufacturer.


• Foreign investments and export growth fuel market development.


• Research and development advancements along with regulatory support aid innovation and quality improvements.


• Contract manufacturing growth is further catalyzing the API sector.

Buy the Latest 2026 Edition: https://www.imarcgroup.com/checkout?id=29480&method=1337

India Active Pharmaceutical Ingredients Market Trends

• The Indian government is promoting domestic API manufacturing to reduce import dependence and enhance self-reliance.


• The Production Linked Incentive (PLI) scheme allocates INR 6,940 crore for boosting manufacture of essential APIs, pharmaceutical intermediates, and key starting materials (KSM).


• Significant investments are being made including expansion of existing manufacturing units and establishment of new facilities.


• 'Pharmaceuticals Vision 2020' with Rs.15,000 crore aims at making India one of the world's leading pharmaceutical manufacturing centers.


• The rising prevalence of chronic diseases pushes the pharmaceutical sector towards API production tailored to these health needs.


• According to a study by Thought Arbitrage Research Institute (TARI), chronic disease prevalence was 116 per 1,000 population in 2021, with two-thirds aged between 26 and 59 years.


• By 2030, non-communicable diseases will contribute about 67% of India’s disease burden, indicating a health emergency.


• This scenario encourages API market growth and diversification.


• Increased contract manufacturing and biosimilars adoption are noteworthy trends.

India Active Pharmaceutical Ingredients Market Segmentation

Drug Type Insights:

• Innovative Active Pharmaceutical Ingredients


• Generic Active Pharmaceutical Ingredients

The report offers a detailed breakup and analysis of innovative and generic active pharmaceutical ingredients by drug type.

Manufacturer Type Insights:

• Captive API Manufacturers


• Merchant API Manufacturers


• Innovative Merchant API Manufacturers


• Generic Merchant API Manufacturers

Includes a detailed analysis of captive and merchant API manufacturers, segregating innovative and generic types.

Synthesis Type Insights:

• Synthetic Active Pharmaceutical Ingredients


• Innovative Synthetic APIs


• Generic Synthetic APIs


• Biotech Active Pharmaceutical Ingredients


• Drug Type: Innovative Biotech APIs, Biosimilars


• Product Type: Monoclonal Antibodies, Vaccines, Cytokines, Others


• Expression System Type: Mammalian Expression System, Microbial Expression System, Yeast Expression System, Others

This section provides an in-depth breakup of synthetic and biotech APIs covering various drug, product, and expression system types.

Therapeutic Application Insights:

• Oncology


• Cardiovascular and Respiratory


• Diabetes


• Central Nervous System Disorders


• Neurological Disorders


• Others

Detailed breakup and analysis based on therapeutic applications targeted by APIs.

Regional Insights

• North India


• South India


• East India


• West India

The market is dominated by North India, with significant market share and growth prospects. The overall India active pharmaceutical ingredients market is expected to grow at a CAGR of 8.10% during the forecast period, supported by regional manufacturing and demand dynamics.

India Active Pharmaceutical Ingredients Market Recent Developments & News

• September 2024: India’s first API fermentation factory in Nalagarh commenced large-scale production.


• The factory achieved yields of up to 6.5% within the first months.


• The facility supplies API to states such as Gujarat and Uttarakhand, meeting 60% of domestic demand.


• Upon reaching peak capacity, it will manufacture 400 tons of potassium clavulanate API annually.

India Active Pharmaceutical Ingredients Market Key Highlights of the Report

• Comprehensive quantitative analysis of market segments and trends from 2019 to 2033.


• Insight into market drivers, challenges, and opportunities.


• Porter’s five forces analysis to assess industry competition and attractiveness.


• Competitive landscape with key player positioning and strategy analysis.


• Detailed company profiles of major market players.


• Scope for 10% free customization and post-sale analyst support.

India Active Pharmaceutical Ingredients Market Key Players

The report offers an in-depth examination of the competitive landscape, including market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant.

Get Your Customized Market Report Instantly:https://www.imarcgroup.com/request?type=report&id=29480&flag=E

Customization Note:If you require any specific information not covered within this report’s scope, we will provide it as part of the customization.

About Us

IMARC Group is a global management consulting firm that helps ambitious changemakers create a lasting impact. The company offers comprehensive market assessment, feasibility studies, incorporation support, regulatory assistance, branding and strategy services, and procurement research.

Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel: (D) +91 120 433 0800

United States: +1-201971-6302